Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease

Experimental Neurology

Volumn 196, Issue 2, 2005, Pages 266-272

  Van Raamsdonk, Jeremy M ^a   Pearson, Jacqueline ^a   Rogers, Daniel A ^a   Lu, Ge ^a   Barakauskas, Vilte E ^b   Barr, Alasdair M ^b   Honer, William G ^b   Hayden, Michael R ^a   Leavitt, Blair R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Eicosapentaenoic acid; Essential fatty acid; Experimental therapeutics; Huntington disease; Motor dysfunction; Neurodegeneration; Transgenic mouse model

Indexed keywords

ICOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID ETHYL ESTER; PHOSPHOPROTEIN DARPP 32;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; BRAIN SIZE; CELL COUNT; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFICACY; EXPERIMENTAL MODEL; FEMALE; HUNTINGTON CHOREA; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; OPEN FIELD BEHAVIOR; OPEN FIELD TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; ROTAROD TEST; TASK PERFORMANCE;

ANIMALS; BEHAVIOR, ANIMAL; CELL COUNT; DISEASE MODELS, ANIMAL; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; EICOSAPENTAENOIC ACID; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXPLORATORY BEHAVIOR; GENE EXPRESSION REGULATION; HUNTINGTON DISEASE; IMMUNOHISTOCHEMISTRY; MICE; MOTOR ACTIVITY; NERVE DEGENERATION; PHOSPHOPYRUVATE HYDRATASE; TIME FACTORS;

EID: 27744478499     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2005.07.021     Document Type: Article

References (28)

1. J.M. Alessandri, P. Guesnet, S. Vancassel, P. Astorg, I. Denis, B. Langelier, S. Aid, C. Poumes-Ballihaut, G. Champeil-Potokar, and M. Lavialle Polyunsaturated fatty acids in the central nervous system: evolution of concepts and nutritional implications throughout life Reprod. Nutr. Dev. 44 2004 509 538
2. T. Babcock, W.S. Helton, and N.J. Espat Eicosapentaenoic acid (EPA): an antiinflammatory omega-3 fat with potential clinical applications Nutrition 16 2000 1116 1118
3. J.A. Bibb, Z. Yan, P. Svenningsson, G.L. Snyder, V.A. Pieribone, A. Horiuchi, A.C. Nairn, A. Messer, and P. Greengard Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice Proc. Natl. Acad. Sci. U. S. A. 97 2000 6809 6814
4. R.M. Bonelli, and P. Hofmann A review of the treatment options for Huntington's disease Expert Opin. Pharmacother. 5 2004 767 776
5. J.J. Clifford, J. Drago, A.L. Natoli, J.Y. Wong, A. Kinsella, J.L. Waddington, and K.S. Vaddadi Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease Neuroscience 109 2002 81 88
6. L. Froyland, L. Madsen, H. Vaagenes, G.K. Totland, J. Auwerx, H. Kryvi, B. Staels, and R.K. Berge Mitochondrion is the principal target for nutritional and pharmacological control of triglyceride metabolism J. Lipid Res. 38 1997 1851 1858
7. P. Harper Huntington's Disease 1996 W.B. Saunders Company Ltd. London
8. M.A. Hickey, and M.F. Chesselet Apoptosis in Huntington's disease Prog. Neuro-psychopharmacol. Biol. Psychiatry 27 2003 255 265
9. P.E. Lonergan, D.S. Martin, D.F. Horrobin, and M.A. Lynch Neuroprotective effect of eicosapentaenoic acid in hippocampus of rats exposed to gamma-irradiation J. Biol. Chem. 277 2002 20804 20811
10. P.E. Lonergan, D.S. Martin, D.F. Horrobin, and M.A. Lynch Neuroprotective actions of eicosapentaenoic acid on lipopolysaccharide-induced dysfunction in rat hippocampus J. Neurochem. 91 2004 20 29
11. V. Macdonald, and G. Halliday Pyramidal cell loss in motor cortices in Huntington's disease Neurobiol. Dis. 10 2002 378 386
12. D.S. Martin, P.E. Lonergan, B. Boland, M.P. Fogarty, M. Brady, D.F. Horrobin, V.A. Campbell, and M.A. Lynch Apoptotic changes in the aged brain are triggered by interleukin-1beta-induced activation of p38 and reversed by treatment with eicosapentaenoic acid J. Biol. Chem. 277 2002 34239 34246
13. T.A. Mori, and L.J. Beilin Omega-3 fatty acids and inflammation Curr. Atheroscler. Rep. 6 2004 461 467
14. A.V. Panov, C.A. Gutekunst, B.R. Leavitt, M.R. Hayden, J.R. Burke, W.J. Strittmatter, and J.T. Greenamyre Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines Nat. Neurosci. 5 2002 731 736
15. B.K. Puri, B.R. Leavitt, M.R. Hayden, C.A. Ross, A. Rosenblatt, J.T. Greenamyre, S. Hersch, K.S. Vadaddi, A. Sword, D.F. Horrobin, M. Manku, and H. Murck Ethyl-EPA in Huntington disease: a double-blind, randomized placebo-controlled trial Neurology 65 2 2005 286 292
16. H.D. Rosas, W.J. Koroshetz, Y.I. Chen, C. Skeuse, M. Vangel, M.E. Cudkowicz, K. Caplan, K. Marek, L.J. Seidman, N. Makris, B.G. Jenkins, and J.M. Goldstein Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis Neurology 60 2003 1615 1620
17. A.H. Sharp, and C.A. Ross Neurobiology of Huntington's disease Neurobiol. Dis. 3 1996 3 15
18. S.K. Singhrao, J.W. Neal, B.P. Morgan, and P. Gasque Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease Exp. Neurol. 159 1999 362 376
19. E.J. Slow, J. van Raamsdonk, D. Rogers, S.H. Coleman, R.K. Graham, Y. Deng, R. Oh, N. Bissada, S.M. Hossain, Y.Z. Yang, X.J. Li, E.M. Simpson, C.A. Gutekunst, B.R. Leavitt, and M.R. Hayden Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease Hum. Mol. Genet. 12 2003 1555 1567
20. T. Suzuki, K. Fukuo, T. Suhara, O. Yasuda, N. Sato, Y. Takemura, M. Tsubakimoto, and T. Ogihara Eicosapentaenoic acid protects endothelial cells against anoikis through restoration of cFLIP Hypertension 42 2003 342 348
21. P. Svenningsson, A. Nishi, G. Fisone, J.A. Girault, A.C. Nairn, and P. Greengard DARPP-32: an integrator of neurotransmission Annu. Rev. Pharmacol. Toxicol. 44 2004 269 296
22. K.S. Vaddadi, E. Soosai, E. Chiu, and P. Dingjan A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids NeuroReport 13 2002 29 33
23. A. van Dellen, J. Welch, R.M. Dixon, P. Cordery, D. York, P. Styles, C. Blakemore, and A.J. Hannan N-acetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntington's disease mice NeuroReport 11 2000 3751 3757
24. J.M. Van Raamsdonk, J. Pearson, E.J. Slow, S.M. Hossain, B.R. Leavitt, and M.R. Hayden Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease J. Neurosci. 25 2005 4169 4180
25. J.M. Van Raamsdonk, J. Pearson, D.A. Rogers, N. Bissada, A.W. Vogl, M.R. Hayden, and B.R. Leavitt Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease Hum. Mol. Genet. 14 2005 1379 1392
26. J.M. Van Raamsdonk, J. Pearson, C.D.C. Bailey, D. Rogers, G.V.W. Johnson, M.R. Hayden, and B.R. Leavitt Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington's disease J. Neurochem. 2005 (Published online Aug 8. 1-9)
27. J.P. Vonsattel, and M. DiFiglia Huntington disease J. Neuropathol. Exp. Neurol. 57 1998 369 384
28. J.M. Ward, J.F. Mahler, R.R. Maronpot, and J.P. Sundberg Pathology of Genetically Engineered Mice 2000 Blackwell Publishing Ames, USA